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Voltage-gated calcium channels are important for the
regulation of renal blood flow and the glomerular filtration
rate. Excitation–contraction coupling in afferent arterioles
is known to require activation of these channels and we
studied their role in the regulation of cortical efferent
arteriolar tone. We used microdissected perfused mouse
efferent arterioles and found a transient vasoconstriction
in response to depolarization with potassium; an effect
abolished by removal of extracellular calcium. The T-type
voltage-gated calcium channel antagonists mibefradil and
nickel blocked this potassium-induced constriction. Further,
constriction by the thromboxane analogue U46619 was
significantly inhibited by mibefradil at a concentration
specific for T-type channels. Using PCR, we found that two
channel subtypes, Cav3.1 and Cav3.2, were expressed in
microdissected efferent arterioles. Cav3.1 was found by
immunocytochemistry to be located in mouse efferent
arterioles, human pre- and postglomerular vasculature, and
Cav3.2 in rat glomerular arterioles. Inhibition of endothelial
nitric oxide synthase by L-NAME or its deletion by gene
knockout changed the potassium-elicited transient
constriction to a sustained response. Low concentrations
of nickel, an agent that blocks Cav3.2, had a similar effect.
Thus, T-type voltage-gated calcium channels are functionally
important for depolarization-induced vasoconstriction and
subsequent dilatation in mouse cortical efferent arterioles.
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Changes in pre- and postglomerular vessel diameters are
involved in regulation of renal blood flow, glomerular
ultrafiltration pressure, and medullary blood flow. These
effects influence glomerular filtration rate and salt and water
homeostasis and thereby blood pressure. Furthermore, the
kidney vascular segments are involved in several pathological
conditions such as diabetes and hypertension. Excitation–-
contraction coupling in renal afferent arteriole involves
voltage-gated calcium channels (Cav). In keeping with the
central role of Cav, the channels are targets for pharmaco-
logical intervention in hypertension.
The family of voltage-gated calcium channels are divided
into high voltage-activated channels (including L-type Cav)
that are activated by a large depolarization, and low voltage-
activated channels (to which the T-type Cav belongs) that
activate after rather limited depolarization.1 Genes encoding
mRNAs for Cav a-subunits have been cloned and the L-type
channels include Cav 1.1–1.4, and T-type channels comprise
three Cav, 3.1–3.3. Vascular smooth muscle cells from
preglomerular vessels and freshly microdissected preglomer-
ular vessels express, among others, Cav1.2, Cav3.1, and
Cav3.2. Postglomerular vessels from rats showed a differential
expression of the voltage-gated calcium channels, with
L- (Cav1.2) and T-type (Cav3.1 and 3.2) subunits expressed
in efferent arterioles from juxtamedullary glomeruli and in
outer medullary vasa recta, whereas no voltage-dependent
calcium channels were detected in cortical efferent arterioles.2
The activation mechanisms that induce vasoconstriction in
afferent and efferent arterioles in the renal cortex
are considered different. Thus, depolarization and Cav are
involved in the mechanisms that lead to vasoconstriction in
the preglomerular vasculature.3,4 In efferent arterioles the
involvement of Cav is less clear. Calcium influx pathways in
efferent vessels have been reported not to be dependent on
depolarization5 and to be resistant to L-type calcium channel
antagonists6 whereas others have shown effects of T-type
antagonists.7 In vivo data confirm the heterogeneity between
afferent and efferent arterioles and an important contribu-
tion from T-type channels has been suggested for efferent
arterioles.8–10 Finally, a recent clinical study showed that
benidipine (a combined L- and T-type antagonist) caused
larger reduction in blood pressure and proteinuria compared
with L-type treatment using amlodipine,11 suggesting a
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vasoconstrictor effect of T-type channels on efferent
arterioles.
The purpose of this study was to determine if voltage-
gated calcium channels are present in mice efferent arterioles,
and if so, whether they contribute to vascular responses.
Furthermore, we investigated the subtype of Cav in post-
glomerular vessels focusing on L- and T-type channels.
Expression and location of Cav were determined by
polymerase chain reaction (PCR) and immunostaining. In
addition, the functional importance was investigated in
isolated mouse perfused efferent arterioles.
RESULTS
Depolarization induced constriction in efferent arterioles
Resting basal diameter of cortical efferent arterioles vessels
was on average 7.9±0.3 mm and application of high
potassium solution (HPS, 100mmol/l potassium) decreased
the diameter to 0.1±0.1 mm. After washout, removal of
extracellular calcium for 1min had no effect on basal
diameter but blocked the potassium-induced response and
the diameter was not significantly different from basal
(Figure 1a). To rule out any nerve-mediated effects, we
tested the potassium-induced constriction in the presence of
an a1-antagonist phentolamine (PHE). Figure 1b shows that
administration of PHE (104mol/l) did not change the basal
diameter in efferent arterioles and HPS application in the
presence of PHE elicited a constriction (from 6.9±0.7 to
0.07±0.05 mm) not different from the HPS response without
PHE treatment (from 6.5±0.3 to 0.6±0.6 mm).
Involvement of calcium channels in the constrictor and
secondary vasodilation responses
Eight individual experiments testing the response to HPS in
the presence of nifedipine showed that the basal diameter of
the vessels was on average 6.6±0.1 mm and HPS treatment
decreased the luminal diameter significantly to 0.0±0.0 mm.
No significant change in blood vessel diameter could be
observed after nifedipine. After incubation with nifedipine
HPS decreased the diameter by 36.6±15.5% to 4.2±1.1 mm
with a rather large variance between experiments (data
not shown).
Concentration–response experiments for mibefradil
showed a blockade of HPS-elicited vasoconstriction
(Figure 2a). The mean basal luminal diameter was
7.2±0.4 mm and HPS led to short complete occlusion of
the arterioles (0.0±0.0 mm). Application of mibefradil
at increasing concentrations (109 to 105mol/l) completely
prevented vasoconstriction after HPS. After washout of
mibefradil the vessels were fully viable. The thromboxane
A2 analogue, U46619, concentration dependently contracted
efferent arterioles with an EC50 of 3 108mol/l. Mibefradil
(107mol/l) significantly inhibited the U46619-induced
constriction at 107mol/l (Figure 2b). Another important
vasoconstrictor angiotensin II also concentration dependently
contracted effect arterioles with maximum response (Emax) at
109mol/l and an EC50 at 1.1 1010mol/l. Owing to
tachyphylaxis the experiment was repeated in the presence of
mibefradil (107mol/l) in another set of arterioles. The
constriction at 109mol/l of Ang II had a tendency be less in
the presence of mibefradil; however it was not significantly
inhibited by the T-type antagonist (Figure 2c).
Another T-type antagonist, nickel chloride (NiCl2), did
not significantly change the resting luminal diameter over
1min (from 7.3±0.4 to 6.9±0.5 mm). However, NiCl2 had
concentration-dependent effects on the response to high
potassium (Figure 3). Exposure to HPS alone elicited a
transient constriction, which completely closed the vessels for
on average 16.2±7.0 s, and which was followed by a dilation.
When low concentrations of NiCl2 were applied, the
secondary vasodilation was blocked, and a significant
increase in the duration of the contraction was observed
(Figure 3a). Thus, in the presence of NiCl2 (10
6mol/l) HPS
elicited a sustained constriction lasting on average
48.2±1.1 s. At 105mol/l of NiCl2 the duration of the
complete closure of the efferent arteriole lasted 46.7±2.1 s
(Figure 3b). At higher concentrations of NiCl2 the initial
contraction elicited by HPS was inhibited. Thus, incomplete
closure of the blood vessels was observed when HPS was
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Figure 1 |Depolarization-induced constriction in mouse
efferent arterioles. (a) Potassium (100 mmol/l) was added to the
bath in the presence (K) and absence of extracellular calcium
(KCa2þ ). Calcium was removed for 1min (Ca2þ ) before
administration of KCa2þ . (b) Potassium-induced contraction in
the presence and absence of phentolamine (PHE) 104mol/l.
‘Basal 1’ and ‘Basal 2’ represent basal luminal diameters before
first and final application of Kþ . Data are means±s.e.m., n¼ 5;
%Po0.05 compared with basal measured at the maximal
constrictor response.
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applied in the presence of NiCl2 10
4mol/l (25.5±7.4) and
at 103mol/l no significant response to HPS was observed
(Figure 3c and d). NiCl2 caused a concentration-dependent
increase in luminal diameter in potassium-constricted
vessels, with an EC50 of 1.67 104mol/l and a significant
inhibition of HPS induced contraction at 103mol/l NiCl2.
For the corresponding areas under curve for increa-
sing concentrations of NiCl2, the following data were
obtained: 76.6±9.8 s mm at 106mol/l, 84.3±14.2 s mm at
105mol/l, 186.6±22.8 s mm at 104mol/l, 373.8±26.2 s mm
at 103mol/l and for HPS alone 261.6±45.3 s mm. Areas
under curve for NiCl2 10
6 and 105mol/l were significantly
different from HPS alone.
Involvement of NO in the secondary vasodilatory response
after depolarization
Under control condition, high potassium elicits a significant
transient constriction in efferent arterioles with complete
closure lasting for 11.0±1.5 s. Incubation with No-nitro-L-
arginine methyl ester hydrochloride (L-NAME) significantly
decreased the basal diameter by 9.3±0.34%, and HPS elicited
a constriction significantly faster than in the absence of
L-NAME. After L-NAME treatment the duration of Kþ -
elicited contraction increased to 53.4±2.0 s (Figure 4a). In
eNOS/ mice the basal diameter before application of HPS
was 8.2±0.6 mm (compared with 8.6±0.7 mm in wild-type
(wt) animals) and after application of HPS the diameter
decreased to 0.0±0.0 mm (Figure 4b). The duration of the
contraction in eNOS/ mice was not statistically signifi-
cantly different to that of wt mice treated with L-NAME but
significantly different from the duration of the vasoconstric-
tion in wt. Thus, the secondary vasodilation after treatment
with HPS is blocked by L-NAME or absence of eNOS.
Acetylcholine elicited dilatation of efferent arterioles
Acetylcholine (Ach)-mediated dilatation was investigated in
vessels preconstricted with 9,11-dideoxy-11a,9a-epoxy-
methanoprostaglandin F2a (U46619) (10
6mol/l) resulted
in a luminal diameter of 1.4±1.4 mm and Ach increased the
luminal diameter to 7.6±0.2 mm. In the presence of L-NAME
and U46619, Ach was unable to change the luminal diameter
significantly (Figure 5a). The Ach-induced response was
significantly different between the groups with and without
L-NAME. In Figure 5b, Ach in the presence of U46619
increased the luminal diameter from 1.1±1.1 to 6.6±
0.3 mm. Simultaneous exposure to NiCl2 (10
6mol/l) led to a
similar increase in diameter to 6.6±0.3 mm.
Expression and localization of T-type calcium channels
in renal vasculature
To detect whether both Cav3.1 and Cav3.2 were expressed in
mouse postglomerular blood vessels, we performed PCR
analysis using specific primers on RNA extracted from
efferent arterioles. Bands of the expected size were observed
for Cav3.1 and Cav3.2 in cortical efferent arterioles and in the
positive control using whole brain (Figure 6). The negative
controls, water and minus reverse transcriptase, showed
no bands.
Next, the distribution of Cav3.1 and Cav3.2 was examined
in kidney sections. Labeling for Cav3.1 was associated with
the entire mouse renal vasculature including glomerular
arterioles (Figure 7a). Acid-treated kidney glomeruli with
attached efferent arterioles showed Cav3.1 protein in cortical
efferent arterioles (Figure 7c). Also human pre- and
postglomerular vasculature expressed Cav3.1 protein.
Figure 7e shows labeled vasa rectae from outer medulla and
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Figure 2 |Concentration–response relationship to mibefradil
in arterioles constricted with Kþ . (a) Mibefradil was
administered at increasing concentrations in the presence of high
potassium and phentolamine (n¼ 6; %Po0.05 compared to
basal). (b) U46619 (107mol/l) elicited constriction in the
presence and absence of mibefradil 107mol/l (Mib)
(n¼ 5; %Po0.05 compared to no mibefradil). (c) Angiotensin
II (109mol/l) elicited constriction in the presence and absence
of mibefradil 107mol/l (Mib) (n¼ 4; %Po0.05 compared to no
mibefradil). Data are means±s.e.m.
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staining of a human afferent arteriole is shown in Figure 7f.
Finally, labeling for Cav3.2 protein was observed in arteries
and arterioles of rat cryosections (Figure 8). Furthermore,
separate experiments using immunofluorescence microscopy
was performed as this method yielded a higher resolution
than DAB staining. In a kidney section, arteries and arterioles
positively labeled for Cav3.2, interestingly capillaries and the
vessels within the glomerulus were also positive for Cav3.2
(Figure 8c). Using higher magnification, one could easily
determined the distribution Cav3.2 in the vessel showing
labeling of vascular smooth muscle cells and endothelial
cells (Figure 8d).
DISCUSSION
Exposure to a high potassium concentration depolarizes renal
preglomerular vessels, activates voltage-gated calcium chan-
nels, and stimulates calcium influx and contractions.
The involvement of Cav in efferent arteriolar contractility
has been unclear but in this study we demonstrate that
depolarization of mouse perfused cortical efferent arterioles
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Figure 3 | Time series for Kþ applications in the presence and absence of NiCl2. (a) K
þ was added to the bath for 1min. After a resting
period the vessels were treated with NiCl2 (10
6mol/l) for 1min before application of Kþ þNiCl2. (b) As (a) except NiCl2 (105mol/l).
(c) As (a) except NiCl2 (10
4mol/l). (d) As (a) except NiCl2 (10
3mol/l). Data are means±s.e.m., n¼ 6.
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Figure 4 | Effect of L-NAME and eNOS deletion on the depolarization-induced response. (a) Kþ induced response for 1min
(Control, black). Inhibition of NO synthases by L-NAME (5 105mol/l) for 10min before application of L-NAME and Kþ (L-NAME, gray).
(b) Kþ response in wild-type and eNOS/ mice (gray). Data are means±s.e.m. (n¼ 5). eNOS, endothelial nitric oxide synthase; L-NAME,
No-nitro-L-arginine methyl ester hydrochloride.
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consistently constricts the blood vessels. Furthermore, our
data suggest that T-type Cav potentially of the Cav3.1 subtype
are responsible for the potassium-elicited constriction
whereas T-type Cav3.2 are involved in the spontaneous
dilatation that occurs in the blood vessels after the initial
constriction.
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Figure 5 | The effect of L-NAME and NiCl2 on acetylcholine-
induced dilation. (a) Acetylcholine (Ach) (106mol/l) induced
dilation in U46619 (106mol/l) preconstricted efferent arterioles
with and without L-NAME (5 105mol/l). (b) Ach (106mol/l)
induced dilation in efferent arterioles preconstricted with U46619
(106mol/l) (Ach). Next, the preconstricted blood vessels were
incubated with NiCl2 (10
6mol/l) for 1min before Ach application.
Data are means±s.e.m. n¼ 4 for (a) and n¼ 6 (b).
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Figure 6 |RT–PCR analysis for Cav3.1 and Cav3.2. RT–PCR
amplification of cDNA from mouse cortical efferent arterioles
(Eff.þ RT) Cav3.1 and 3.2. Negative controls were RT (Eff.RT):
omission of reverse transcriptase during reverse transcription, and
H2O: water instead of cDNA in the PCR. Positive control was brain.
RT–PCR, reverse transcription–polymerase chain reaction.
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Figure 7 | Immunohistochemistry for Cav3.1. Mouse sections
(a) or isolated efferent arteriole (c) were labeled with anti-Cav3.1
antibody. Omission of primary antibody served as control (b, d).
Labeling of human vasa recta (e) and glomerular arteriole (f) using
anti-Cav3.1 antibody.
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Figure 8 | Immunohistochemistry for Cav3.2. Rat cryosections
(a, c, d) were labeled with anti-Cav3.2 antibody. Omission of
primary antibody served as control (b).
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Depolarizing the efferent arteriole led to a contraction,
which was totally dependent on influx of extracellular
calcium suggesting involvement of Cav. Activation of T-type
and L-type Cav has been shown to mediate a1-adrenoceptor-
mediated constriction in guinea pig vas deferens.12 Whether
the contraction of efferent arterioles was mediated through
activation of the sympathetic nerve terminals and norepi-
nephrine release was tested with PHE as norepinephrine
mediates contraction mainly through smooth muscle
a1-adrenergic receptors. Because pretreatment with PHE
did not change the potassium-elicited response, the response
must be independent of norepinephrine and thus probably
mediated by a direct smooth muscle cell response. The
participation of T-type calcium channels in excitation–con-
traction coupling was shown by the effects of mibefradil and
nickel. Mibefradil selectively inhibits T-type currents at low
concentrations with an EC50 about 10 nmol/l
13,14 and
the Cav3.1 channel is relatively sensitive to mibefradil.
13 In
this study, mibefradil blocked Kþ -induced contraction at
109 mol/l. Moreover, Ni2þ dose dependently inhibited Kþ -
mediated contraction with an EC50 of 1.67 104mol/l.
Nickel is a blocker of T-type channels (Cav3.1, Cav3.2, and
Cav3.3) but their sensitivity to nickel differs.
15 T-type
currents elicited by a13.1 subunits are blocked by Ni
2þ in
the range 0.5–1 mmol/l,13 whereas the Cav3.2 channel is
highly sensitive to nickel (EC50 of around 10 mmol/l).
16,17 The
high concentrations of Ni2þ necessary for blockade of the
constriction together with the total inhibition of the response
by low-dose mibefradil suggest that Cav3.1 are involved in the
excitation contraction mechanism in the efferent arteriole.
Nifedipine (L-type antagonist) had variable effects on
efferent arterioles.
For postglomerular vessels, the microdissection technique
allowed us to isolate mRNA from cortical efferent arterioles
including both endothelial and vascular smooth muscle cells.
In agreement with the functional data, mRNA for Cav3.1 and
3.2 a1-subunits was expressed in isolated cortical efferent
arterioles. Immunohistochemistry for Cav3.1 and 3.2
proteins showed the expected labeling of all large vessels
and glomerular vessels. The immunostaining for Cav3.1 was
repeated by mounting an efferent arteriole with two
micropipettes in a tissue bath mounted on an inverted
microscope, and making the entire staining procedure on one
specimen at the time confirmed that Cav3.1 is expressed in
mouse cortical efferent arterioles. Furthermore, Cav3.1 was
also observed in human renal vasculature, in both pre- and
postglomerular vessels, suggesting that our results could
apply to humans. Antibodies specific for the T-type subunit
Cav3.2 did not work in the mouse and the experiments were
performed on rat sections, in which immunoflourescence
microscopy showed the presence of Cav3.2 in rodent renal
arterioles in both vascular smooth muscle cells and
endothelial cells including cells in the capillaries. A previous
study has shown a marked heterogeneity in the expression
pattern of calcium channels in renal resistance vessels, with
L- (Cav1.2) and T-type (Cav3.1 and 3.2) subunits expressed
in efferent arterioles from juxtamedullary glomeruli and in
outer medullary vasa recta, but no voltage-dependent
calcium channels detected in cortical efferent arterioles. This
lack of Cav observed in rat cortical efferent arterioles
2
suggests a species difference between rat and mouse, which
explains the large contractility of mouse efferent arterioles
after depolarization.
In agreement with this, Feng et al.18 showed that an L-type
antagonist dilated afferent arterioles in rats whereas it had no
effect on efferent arterioles. In contrast, T-type blockade
dilated both afferent and efferent arterioles. Furthermore,
in vivo studies have shown that T-type activity contributes
significantly to efferent arteriolar function8 and that L-type
antagonists lead to increased filtration fraction corresponding
to an dilatation of afferent but not efferent arterioles, whereas
T-type antagonists caused a lower increase in filtration
fraction.8 Substances important for efferent arteriolar func-
tion in vivo such as angiotensin II and thromboxane were also
affected by inhibition of T-type channels. Constriction
elicited by the thromboxane analogue U46619 was signifi-
cantly inhibited whereas a smaller response was observed for
the angiotensin II-induced response. The lack of significant
inhibition of the angiotensin II-elicited response by mibe-
fradil is in agreement with a previous finding by Loutzenhiser
and Loutzenhiser5 who showed that angiotensin II-induced
constriction in efferent arterioles is dependent on activation
of store-operated calcium channels. Thus, T-type channels of
the Cav3.1 subtype seem to be important in the excitation–-
contraction response of efferent arterioles and therefore
important for the regulation of glomerular filtration rate
and filtration fraction. Calcium blockers of the L-type
are widely used in conditions such as hypertension but
several recent studies have suggested that T-type blockers
have additional beneficial effects. In a changeover study,
benidipine (L- and T-type antagonist) caused larger reduc-
tion in blood pressure and proteinuria compared to L-type
treatment using amlodipine.11 The observation of superior
renoprotective effects with a combined L- and T-type
treatment is in agreement with the current demonstration
of a vasoconstrictor effect of T-type channels on efferent
arterioles.
To our initial surprise Ni2þ in low concentrations did not
inhibit the constriction of efferent arterioles but rather
potentiated the response. Thus, NiCl2 (10
6mol/l) changed
the potassium-elicited constriction from a transient response
to a sustained response lasting the total period of potassium
administration. As described previously, Cav3.2 is highly
sensitive to Ni2þ (EC50 of about 10 mmol/l).
16,17 Cav3.2
mRNAwas present in mouse efferent arterioles, and all blood
vessels observed by immunohistochemistry showed labeling
for Cav3.2 in rat smooth muscle cells and endothelial cells.
An attempt to confirm the involvement of Cav3.2 with siRNA
techniques was unsuccessful because the technical procedures
led to loss of endothelial function. On the basis of our results,
we propose that inhibition of Cav3.2 blocks the spontaneous
dilatation occurring in perfused efferent arterioles after
448 Kidney International (2011) 79, 443–451
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depolarization, although a definitive answer has to await
results from Cav3.2
/ mice.
The secondary dilatation observed in efferent arterioles
after depolarization was likely to be dependent on endothelial
NO production, because it was inhibited by L-NAME and it
was absent in eNOS/ mice. In rabbit afferent arterioles,
depolarization induces contraction by increasing smooth
muscle intracellular calcium concentration, which is followed
by calcium increase in the endothelium where it stimulates
NO production. This, in turn, curtails vasoconstriction by
reducing the calcium sensitivity of the contractile apparatus
of the smooth muscle cells.19 In the efferent arterioles our
new data are consistent with the view that the activation
of eNOS involves calcium influx mediated by activation of
Cav3.2 located on endothelial cells.
A similar role of endothelial T-type channels (Cav3.2) has
been suggested in longitudinal conduction of vasodilator
responses through an endothelium-dependent mechanism
depending on activation of Cav3.2 and calcium-induced
eNOS activation.20 The existence of voltage-gated calcium
channels in endothelial cells has been somewhat controver-
sial, but Cav3.2 has been shown in endothelial cells of small
mesenteric arterioles.21 Lung microvascular endothelial cells
express Cav3.1
22 that carries flow-sensitive calcium fluxes
which are blocked by mibefradil.23
Cav3.2-deficient mice have normal vasoconstrictor
responses but they show reduced relaxation of coronary
vascular smooth muscle after Ach and nitroprusside. Ni2þ
had similar effect in wt animals.24 The authors suggested that
Cav3.2 is coupled to the large calcium-activated potassium
channel (BKca) and that inhibition/deletion of Cav3.2 led to
decreased BKca activity and impaired dilatation. We cannot
exclude that a similar interaction between a Cav3.2 and BKca
may occur in the vascular smooth muscle cells of the efferent
arteriole, but in our experiments the vasodilator effect of Ach
was not inhibited by Ni2þ .
Acetylcholine activates muscarinic receptors on endothe-
lial cells and causes NO production by stimulation of eNOS
through release of calcium from intracellular stores. In
contrast, the potassium-dependent activation of NO produc-
tion involves influx of extracellular calcium. The observation
that the potassium-dependent dilation was blocked by Ni2þ
whereas the ACh-induced dilation was not, suggests that the
effect of Ni2þ at low concentrations is neither due to
impairment of NO production nor due to impairment of the
response to NO in the smooth muscle. This is in agreement
with the suggestion that activation of eNOS involves calcium
influx mediated by activation of Cav3.2 located on endothe-
lial cells for the potassium-induced response but not for the
Ach-induced response.
In conclusion, mouse cortical efferent arterioles express
T-type calcium channels that are involved in both contrac-
tion probably through Cav3.1 and dilatation through Cav3.2.
These observations could be relevant for the understanding of
regulation of glomerular filtration rate and pressure. The
opposite effects of the two T-type channels suggest that
antagonists with specific Cav3.1-blocking properties would have
clinical advantages over more unspecific T-type antagonists.
MATERIALS AND METHODS
Animals
The experimental protocol was approved by the Danish Animal
Experiments Inspectorate under the Danish Ministry of Justice and
animal care followed the guidelines of the National Institutes of
Health. Male and female C57BL/6 mice (wt; Taconic, Ejby,
Denmark), eNOS/ mice (C57BL/6 background, backcrossed for
more than 10 generations; Jackson Laboratory, Bar Harbor, ME), and
rats (Sprague–Dawley) had free access to rodent chow and tap water.
Perfused efferent arterioles
Mouse cortical efferent arterioles with attached glomeruli were
microdissected in Dulbecco’s modified Eagle’s medium/F12 (4 1C)
and perfused retrogradely as described previously.25 The efferent
arteriole was identified by appearance and its location was compared
to the preglomerular vasculature, and was transferred to a
thermostated (37 1C) chamber (Warner, Hamden, CT) containing
Dulbecco’s modified Eagle’s medium/F12 (saturated 5% CO2 in air)
with 0.1% bovine serum albumin. The chamber was mounted on an
inverted microscope (Zeiss Axiovert 10, Oberkochen, Germany).
Perfusion occurred by aspiration of the arteriole into a pipette and
cannulation with a second pipette followed by increase in driving
pressure until the vessel opened, indicating perfusion. The
experiments were recorded using a digital camera (DAGE MTI,
Michigan City, IN). One frame per second was stored on a
computer, using a frame grapper card (Pixel Smart). Images were
transferred to custom-made imaging software FluoroFix (produced
by Rozh Husain Al-Mashhadi, University of Southern Denmark)
and luminal diameter was determined at the most reactive part of
the arteriole and at the time with the maximal response. All
experimental protocols started with a period of equilibration after
the perfusion was established and vessel viability were tested by
administration of an HPS (100mmol/l potassium) added to the
bath. All experiments ended by a viability test using HPS or in the
absence of contraction ANG II (106mol/l) was applied.
Extraluminal calcium was removed for 1min and the efferent
arteriole was challenged with HPS minus calcium for 1min. To test
for potential involvement of nerve-mediated responses, we applied
the a-adrenoceptor antagonist PHE 104mol/l to the chamber for
10min followed by HPS. The effect of nifedipine (5 106mol/l;
Sigma-Aldrich, St Louis, MO) on HPS-elicited constriction was
also tested.
Concentration–response curves were obtained for mibefradil
(Sigma-Aldrich) in the concentration range 109 to 105mol/l.
Each concentration of mibefradil was applied for 5min in the
presence of PHE followed by 1min HPS administration; this was
repeated for each mibefradil concentration. The effect mibefradil
was tested on U46619 and angiotensin II-induced constrictions.
Increasing concentrations of either U46619 (108, 3 108,
6 108, 107mol/l) or angiotensin II (1010 to 108mol/l) were
applied for 3min in the presence and absence of mibefradil
(107mol/l). Concentration–response kinetics was also determined
for another T-type antagonist NiCl2 (Sigma-Aldrich) in the presence
of PHE by adding the compound to the bath for 1min at increasing
concentrations (106 to 103mol/l) followed by HPS for 1min.
In the next series of experiments, the vessels were incubated with
L-NAME (5 105mol/l; Sigma-Aldrich) and PHE (105mol/l) for
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20min and the contractility profile to HPS (1min) was investigated.
Furthermore, the time line for the constrictor response to HPS in
eNOS/ mice was determined.
Finally, the effect of blocking T-type channels or eNOS for Ach
(Sigma-Aldrich)-mediated dilatation was investigated. Efferent
arterioles were preconstricted with thromboxane-prostanoid recep-
tor agonist U46619 106mol/l (Sigma-Aldrich) for 3min and Ach
106mol/l was applied in the presence of U46619 for 2min. After a
resting period, the vessels were incubated with L-NAME
5 105mol/l for 20min and application of U46619 and Ach was
repeated. In the last series of experiments, the Ach (106mol/l)
induced dilatation in U46619-treated vessels was determined and
subsequently the response was assessed in the presence of NiCl2
(106mol/l, 1min pretreatment).
High potassium solution composition in mmol/l: NaHCO3 25,
NaCl 20, KCl 95, MgSO4 1.2, K2HPO4 2.5, HEPES 10, CaCl2 1.3,
glucose 5.
Reverse transcription (RT–PCR)
Efferent arterioles were dissected and RNA extracted by acid-
guanidinium-phenol-chloroform extraction.26 RT–PCR was per-
formed on 6–7 efferent arterioles with an annealing temperature
of 50 1C, 32 cycles. Cav3.1 (forward): 50-GAACGTGAGGCCAA
GAGT-30, reverse 50-GCTCGTAAGCGTTCCCCT-30 coving 221 bp.
Cav3.2 (forward): 5
0-GCTCTCCCCCGTCTACTTCG-30, reverse
50-AGATACTTTGCGCACGACCAGG-30 covering 247 bp. b-Actin
was copied from Yu et al.27
Immunohistochemistry
The use of human material was approved by Danish Ethical
Committee and all subjects gave informed consent. The humane
renal material comes from patients that have their kidneys removed
due to cancer or cysts, the part of the kidney with normal tissue was
used. Cav3.1: Paraffin-embedded sections of mouse and human
kidneys were treated with 0.2% Triton X followed by 0.5% hydrogen
peroxide for 5min and 3% bovine serum albumin. Next the sections
were incubated overnight using primary rabbit anti-Cav3.1 anti-
body28 diluted 1:500. Cav3.2: Cryosections (5mm) from rat kidneys
were permeabilized by 0.5% Triton X and endogenous peroxidases
were blocked by incubation with 0.5% hydrogen peroxide for 10min
followed by 3% goat serum. Next, the sections were incubated with
primary rabbit anti-Cav3.2 antibody (Alomone Labs, Jerusalem,
Israel) diluted 1:50. Secondary antibody goat anti-rabbit IgG,
horseradish-peroxidase-labeled (Dako, Glostrup, Denmark) or
Alexa 568-conjugated goat anti-rabbit (Molecular Probes, Eugene,
OR) diluted 1:1000 was applied. Horseradish-peroxidase-labeled
sections were stained with diaminobenzidine (DABþ substrate–-
chromogen system; Dako) and counterstained with hematoxylin.
Glomeruli with attached cortical efferent arterioles and preglo-
merular vascular trees were microdissected from HCl macerated
mouse kidney. Staining for Cav3.1 of preglomerular specimens was
carried out on a slide while the single efferent arterioles were
transferred to a chamber on an inverted microscope and held with
glass pipettes.2,29 The protocol was similar to the Cav3.1 staining
described for mouse kidney sections.
Statistical analysis
Data are presented as means±s.e.m. Significance of changes was
calculated by one-way analysis of variance with Bonferroni reduction
for multiple comparisons and Student’s t-test for comparison of two
groups. Po0.05 was considered statistically significant.
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